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Abstract 
Four forms of basic fibroblast growth factor (bFGF or FGF-2), using one AUG (155 amino acids) and three upstream CUG (210, 201 and 
196 amino acids) start codons, were synthesized through an alternative use of initiation codons. The 210-amino acid form of FGF-2 (210FGF-2) 
was expressed in a plasmid vector under the control of a bacteriophage T7 RNA polymerase promoter system in Escherichia coli. Characterization 
of the purified protein was performed by electrospray mass spectrometry and Edman degradation. The recombinant 210FGF-2 produced in E. coli 
had a mitogenic activity similar to the 146-amino acid form extracted from tissues. 
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1. Introduction 
Basic fibroblast growth factor (bFGF or FGF-2) is a 
mitogen and differentiation factor for a variety of cells 
including vascular endothelial cells as well as being a 
potent angiogenic factor [l-3]. Its was originally identi- 
fied in the bovine pituitary by D. Gospodarovicz in 1974 
[4]. FGF-2 is prototypic of a family of nine heparin- 
binding structurally related peptides (for review, see [5]). 
At least four human genes encode high affinity cell sur- 
face protein tyrosine kinase receptors (FGFR) [6,7]. The 
complexity of the FGFR family is increased by the alter- 
native splicing of mRNA [S]. The biological activity of 
FGF-2 also requires low affinity heparan-sulfate pro- 
teoglycans (HSPG) binding sites located both on the cell 
surface and in the extracellular matrix [9]. 
Because of the potential therapeutic value of FGF-2, 
laboratories have used the DNA technique to produce 
recombinant proteins for research purposes. Since 
cDNAs corresponding to bovine and human FGF-2 
mRNA have been cloned [l&12], much work has been 
carried out to establish systems for the production of 
large quantities of recombinant FGF-2 (rFGF-2) 
[13-191. 
High molecular weight forms of FGF-2 have been 
described [20,21]. Analysis of an extended hepatoma 
FGF-2 cDNA revealed unusual start codons [22]: pro- 
teins result from an alternative initiation of translation 
at an AUG (155FGF-2, 155 amino acids: 18 kDa) or at 
three inframe upstream CUGs (210FGF-2, 210 amino 
acids: 24 kDa, 201 amino acids: 22.5 kDa and 196 amino 
*Corresponding author. Fax: (33) 6226-4012. 
acids: 22 kDa) [22,23]. The high molecular weight forms 
of FGF-2 contain a glycine-arginine-rich domain where 
arginines can be dimethylated [24]. The multiple FGF-2 
isoforms are localized in different subcellular compart- 
ments: the three high molecular weight forms contain a 
nuclear localization sequence (NLS) in their NH,-termi- 
nal part and can address a reporter protein to the nucleus 
while the 18 kDa form remains mainly cytoplasmic [25]. 
The same distribution pattern was observed in trans- 
fected cells constitutively producing one or other form, 
and their expression correlated to modifications of the 
phenotypes, the different FGF-2 isoforms appear to play 
specific roles in the control of cell metabolism [26,27]. 
The high molecular weight form of FGF-2 (210 amino 
acids) is produced by a wide variety of cell lines including 
hepatoma cells in which it may be involved in 
hepatomacarcinogenesis [20,28]. 
The purpose of this study was to characterize the bio- 
logical activities of the different FGF-2 to get an insight 
into the significance of such diversity. Therefore, in this 
communication, we report the construction of an expres- 
sion plasmid that directs the synthesis of r210FGF-2 in 
E. coli. We also describe the purification and structural 
characterization of the purified recombinant 210FGF-2 
and evaluate the biological activity of the purified form. 
2. Materials and methods 
2.1. Construction of FGF-2 expression vector 
The cDNA encoding the 210FGF-2 [22] was cloned in the pT7 ex- 
pression plasmid pET3a [29] between NdeI and BamHI sites. In this 
construct he CTG initiation codon was substituted by an ATG which 
was part of the NdeI site. This mutagenesis was generated by double- 
stranded oligonucleotide (S’TATGGGGGACCGC3’ and S’GGTCC- 
CCCA3’) insertion harboring NdeI and Sac11 cohesive ends. 
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2.2. FGF-2 production in E. coli 
The transformed bacteria, BL2l(DE3)pLysS, were grown on plates 
containing 100 &ml ampicillin, 0.5 mg/ml methicillin and 25 &ml 
chloramphenicol at 37°C until colonies were visible. Colonies were 
grown overnight in Luria broth (Gibco) and inoculated into ‘terrific 
broth’ [30] with antibiotics, shaken at 37°C to give 0.02 absorbance at 
600 nm. When the absorbance reached 0.6 at 600 nm, IPTG was added 
to the medium to a final concentration of 1 mM and growth was 
prolonged for 2 h. 
2.3. Purification of recombinant FGF-2 
The cells were harvested 2 h after postinduction by centrifugation 
5000 rpm at 4°C for 10 min. The cell pellets were resuspended in 50 mM 
Tris-HCl, pH 7.3, with protease inhibitors (PMSF 1 mM, aprotinin 
2 &ml, leupeptin 2 pg/ml). The cells were lysed by three cycles of 
freezing at -8O”C, and sonicated 5 x 20 s. The cell lysate was adjusted 
to 0.7 M NaCl and centrifuged 100,000 x g for 60 min at 4°C. 
Heparin-Sepharose affinity chromatography. The supernatant frac- 
tion containing the recombinant FGF-2 was applied directly to a col- 
umn packed with heparin-Sepharose CL-6B (Pharmacia, 1 ml of resin) 
previously equilibrated with 10 mM Tris-HCI, pH 7.3, NaC10.7 M. The 
column was washed with equilibration buffer and then with buffer 
containing 1 M NaCl until absorbance at 280 nm (A& of the column 
effluent reached the baseline value. The recombinant FGF-2 was eluted 
with 2.3 M NaCl in Tris buffer. 
Cationic exchange chromatography. Fractions of the heparin-Sepha- 
rose affinity chromatography were desalted using gel filtration (NAP- 
10 column, Pharmacia) and loaded on to a column (6 x 90 mm) packed 
with 3 ml of S-Zephyr (Sepracor) equilibrated with 50 mM Tris-HCI, 
pH 8.0. The column was washed until A,,, reached the baseline value. 
The proteins were eluted with a linear gradient of O-2 M NaCl in Tris 
buffer for 40 min. 
Protein determination and SDS-PAGE. The concentration of total 
protein at each step was determined with the Biorad Protein Assay 
(BioRad Labs) or the BCA technique (Pierce). 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were per- 
formed as described [31]. Proteins were revealed by Coomassie brillant 
blue R 250 or silver staining [32]. 
Zmmunoblot analysis. Immunoblot analysis was done as previously 
described [26] using rabbit anti-FGF-2 polyclonal antibody (Sigma) or 
rabbit anti-210 amino acid FGF-2-NH,-terminus serum. 
HPLC analysis. For mass spectrometric analysis, recombinant 
FGF-2 was desalted and concentrated b reverse phase HPLC on a 
nucleosil C4 column (250 x 4.6 mm, 300 8: 5 pm). The elution system 
was 0.1% TFA (solvent A) and 0.07% TFA in acetonitrile (Solvent B). 
A portion of the heparin-Sepharose affinity chromatography fractions 
was loaded on to the column equilibrated with solvent A and washed 
with solvent A for 5 min. The protein was eluted with a gradient of 
acetonitrile (up to 60%) at a flow rate of 1 ml/min. 
2.4. Structural characterization of FGF-2 
Electrospray mass spectrometric analysis. A freeze-dried sample of 
HPLC-purified r2lOFGF-2 was dissolved in H,O/acetonitrile (1: 1) 
containing 1% formic acid to a final concentration of about 10 pmol/@. 
Electrospray mass spectrometric analysis was carried out by injecting 
10 ,~l of this solution into a Trio 2000 mass spectrometer (VG Analyt- 
ical) consisting of an electrospray ion source followed by a quadrupole 
mass analyser, at a flow rate of 4 @min. The mass spectrometer was 
scanned over m/z 800-1400 in 20 s at a one mass unit resolution. Data 
were acquired by summing ten scans to obtain the final spectrum; 
molecular species produced a series of multiply charged ions from 
which the molecular mass was determined by simple data system rou- 
tines. Mass scale calibration employed the multiply charged ions from 
a separate introduction of myoglobin (average molecular mass 16,950.6 
kDa); the reported molecular masses are the average values which take 
into account all the natural isotopic contributions. 
Protein sequencing. Automated Edman degradation of r2 1 OFGF-2 
was carried out on a Applied Biosystems 470A protein sequencer. 
Phenylthioidantoin derivatives were identified by HPLC after auto- 
matic injection in to an Applied Biosystem analyser 120A, coupled to 
the sequencer. 
2.5. Production of rabbit polyclonal antibodies directed against the 
N-terminal domain of FGF-2 
Immune sera were raised in rabbit against a synthetic peptide, situ- 
ated between residues 39-53 in the 2lOFGF-2 sequence, and conjugated 
to bovine serum albumin (BSA) with glutaraldehyde. Antibodies were 
purified on an affinity column bearing synthetic polypeptide antigens. 
After extensive washing with MOPS 0.1 M, pH 9, the bound material 
was eluted with glycind, 0.2 M, pH 2.8, immediately neutralized with 
Tris, pH 8.5 and dialysed against 10% glycerol in phosphate buffered 
saline, 0.2% BSA before use. 
2.6. Biological assay 
10“ ABAE cells were seeded per 35 mm tissue culture dishes. The 
different forms of FGF-2 were then added every two days to the indi- 
cated final concentration. On day 4, the cells were harvested and viable 
cell numbers were quantitated by counting (Coulter counter Model 
ZM). 
3. Results and discussion 
3.1. Production of r21OFGF-2 
In order to express rFGF-2 at high levels in E. coli, the 
cDNA encoding the protein was cloned in the pT7 ex- 
pression plasmid pET3a (Fig. 1). Bacterial strain E. coli 
BL21(DE3) pLysS was routinely used to produce 
rFGF-2. This system gave results for r146FGF-2 (un- 
published results) comparable to those already described 
[13]. A maximum of 1 mg protein per 1 liter of culture 
medium was obtained for r210FGF-2. We postulate that 
this difference in production efficiency results from the 
5’ end mRNA structure encoding the N-terminal exten- 
sion of the r210FGF-2 which is 86% G/C rich (versus 
58% for the 146 amino acids encoding part) and that is 
deleted in the mRNA encoding the 146 amino acid pro- 
tein. In addition, the presence of repetitive sequences 
encoding Gly-Arg could induce some translational disor- 
ders. 
3.2. Pur$cation of the r21OFGF-2 
Like r146FGF-2, most of the r210FGF-2 remained 
soluble in bacterial cells and was recovered (60%) in the 
soluble fraction after cell breakage. This fraction was 
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Fig. 1. Schematic diagram of the pRFC9 expression vector allowing the 
production of r2lOFGF-2. 
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Fig. 2. SDS-PAGE analysis of bacterial proteins from E. coli IPTG induced cells transformed with the pRFC9 plasmid. (A) Coomassie blue staining. 
Lane 1 = total proteins solubilized (SlOO); lane 2-4 = fractions from the heparin-Sepharose affinity column eluted by 2.3 M NaCl. (B) Immunoblot 
analysis of the heparin-Sepharose affinity purified r210FGF-2 with a serum raised against residues 65 to 88 in the 210 amino acid sequence (lane 
1) and with an anti-peptide serum raised against residues 39 to 53 in the sequence of the r210FGF-2 (lane 2). Arrows show the truncated form of 
r210FGF-2 (trFGF-2) and the N-terminal peptide (N-peptide) resulting from the cleveage of the r210FGF-2. (C) Shematic representation of the 
peptide residues recognized by the two different sera. 
directly applied to heparin-Sepharose affinity chroma- 
tography. Fig. 2 shows SDS-PAGE analysis of individ- 
ual fractions from the heparin-Sepharose affinity chrom- 
atography, visualized by Coomassie blue staining. The 
apparent molecular weight of r210FGF-2 was 24 kDa 
but an additional major contaminant of about 17 kDa 
(Fig. 2A) was routinely observed. This additional 17 kDa 
heparin binding protein was related to FGF-2 since it 
was recognized by serum directed against the peptide 
from residues 65 to 88 in the r210FGF-2 sequence 
(Fig. 2B, lane 1). In order to further characterize the 
r2 IOFGF-2, we developed a specific polyclonal antibody 
directed against a peptide only present in the 210FGF-2 
form (residue 39 to 53 in the r210FGF-2 sequence). In 
immunoblot analysis (Fig. 2B), this serum recognizes the 
24 kDa form and an additional 6.5 kDa peptide, but not 
Table 1 
Amino-terminal sequences of rFGF-2 isolated from E. coli, expressed 
in amino acid single letter code 
210 amino acid FGF-2 GDRGR 
210 amino acid rFGF-2 predicted from gene+ MGDRGR 
146 amino acid FGF-2# PALPE 
trFGF-2 (T)LPALPE 
heFGF-2* TLPALPE 
‘The predicted sequence of human basic FGF based on the nucleotide 
sequence of the basic FGF gene [22]. 
‘The sequence of the bovine brain and pituitary basic FGF as deter- 
mined [l]. 
*The sequence of a trypic peptide of heFGF that has been isolated after 
extraction at neutral pH [38]. 
the 17 kDa form (Fig. 2B, lane 2). This result suggests 
that, even if all steps were done in the presence of a 
cocktail of protease inhibitors, a proteolysis event oc- 
curred during preparation. The 6.5 kDa peptide must 
correspond to the N-terminal part of 210FGF-2 and the 
17 kDa form to the C-terminal part (Fig. 2B). Further 
characterization of the 17 kDa form was done using 
Edmann degradation (Table 1). The sequence estab- 
lished that the N-terminus corresponds to residue 63 in 
the sequence of r210FGF-2 leading to a protein of 148 
amino acids. The 148 amino acid form could not result 
from an internal initiation of the translation since there 
is no methionine or other unusual initiation codon near 
the cleavage site (SIT”TLP). The same truncated form 
was also observed in extracts of eukaryotic cells produc- 
ing the 210FGF-2 form (data not shown) and was de- 
scribed as artefactual degradation occurring during stor- 
age of tissues at -20°C [28,33]. Futhermore, we and 
others never identified such a maturation product after 
the 155FGF-2 form production suggesting that the proc- 
essing recognition site is not fully present in the 155 
amino acid form [15,18,19]. So the 148 amino acid form 
seems to be a specific degradation product of the high 
molecular weight form of FGF-2. The three dimentional 
structure of the high molecular weight form of FGF-2 
could allow the exposure of this sequence that would 
become a highly sensitive ndoproteolytic site. Neverthe- 
less we cannot exclude that the 210FGF-2 presents a 
self-cleaving activity in its NH,-terminus domain as has 
been demonstrated for nucleolin, a protein that also ex- 
hibits a glycine-arginine-rich domain [34]. In all events 
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Fig. 3. Electrospray mass spectrometric analysis of r210FGF-2 purified by HPLC. All peaks correspond to the same protein associated with a variable 
number of protons. The calculated molecular mass was 22,485.75 Da. Inset: HPLC elution pattern of the 210 amino acid form containing in the HSAC 
fraction. The protein was injected onto a C4 column and eluted in 20 min (1 .O mhmin) with a linear gradient of 20% to 60% acetonitrile containing 
0.1% trifluoroacetic acid. 
the presence of the 17 kDa 
cells must be correlated to 
forms. 
form in FGF-2 producing 
the synthesis of the large 
3.3. Structural characterization 
unrelated contaminants or correspond to the 17 kDa 
FGF-2 form present in the heparin-Sepharose affinity 
chromatography fractions. A sample of r210FGF-2 was 
subjected to electrospray mass spectrometry. Multiply 
_ 
charged tons were obtained allowing calculation of the 
molecular mass (Fig. 3). The average molecular mass of 
22,485.75 + 4.3 Da agreed with that predicted on the 
basis of the amino acid sequence (22,487.8; with the mass 
of the initial formylmethionine that is not present in the 
mature protein substracted [35]). 
Structural characterization of the r210FGF-2 purified 
from the bacterial cells was done using a mass spectro- 
metric technique which allowed accurate determination 
of the molecular masses of large biomolecules. 
Fractions from the heparin-Sepharose affinity chrom- 
atography were subjected to reverse phase HPLC analy- 
sis. The Fig. 3 inset shows a typical chromatogram ob- 
tained using a C4 column. Analysis of the major peak by 
SDS-PAGE and immunoblotting revealed homogenous 
r210FGF-2 (data not shown). The minor peaks were 
3.4. PuriJication of biological active rZIOFGF-2 to 
homogeneity 
A further purification step was carried out by running 
the r210FGF-2 fractions, from the heparin-Sepharose 
Fig. 4. Cationic exchange S-Zephyr chromatography and SDS-PAGE analysis of the eluted fractions. The r210FGF-2 (fraction from the heparin- 
Sepharose affinity chromatography) was purified on anion exchange chromatography, S-Zephyr (Sepracor) using a linear gradient from 0 to 2 M 
NaCl. Inset: (A) Coomassie blue staining of the major pit. (B) Immunoblotting with anti-FGF-2 antibody and peroxidase linked second antibody. 
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Fig. 5. Immunoblot analysis of FGF-2 proteins produced in E. coli or 
SK-Hepl cells. Immunoblot analysis of FGF-2 proteins was carried out 
with an anti FGF-2 antibody (Oncoscience). Lane 1 = purified protein 
expressed in E. coli; lane 2 = FGF-2 from SK-Hepl producing cells. 
affinity chromatography, on anion exchange chromatog- 
raphy, S-Zephyr (Sepracor). The samples were desalted 
using gel filtration and applied to the column. r210FGF- 
2 protein was separated from the 17 kDa form by a linear 
salt gradient (0 to 2 M NaCl) as shown in Fig. 4. The Fig. 
4 inset indicates that the major pit was r210FGF-2 as 
revealed by silver staining (lane A) and immunoblotting 
(lane B). This purified form was used as follows to test 
biological activities. 
3.5. Comparison of r21OFGF-2 with the protein produced 
in eukaryotic cells 
Fig. 5 shows that the r210FGF-2 produced in E. coli 
(lane 1) has a smaller apparent molecular weight than the 
210FGF-2 naturally expressed in SK-Hepl (lane 2). The 
apparent size of the proteins expressed in mammalian 
cells was approximately 1 kDa higher than r210FGF-2. 
We suspected a post-translational modification of the 
high molecular weight form of FGF-2 as was already 
suggested [36]. According to Florkiewicz this modifica- 
FGF-2 (@ml) 
0 r 146FGF-2 q r2lOFGF-2 
Fig. 6. Biological activity of the r210FGF-2 in ABAE cells. lo4 cells 
were seeded per 35 mm tissue culture dishes, rl46FGF-2 or r210FGF-2 
were added every two days to the indicated final concentration. On day 
4, the cells were harvested and counted. 
21 
tion is specific of the high molecular weight forms since 
155FGF-2 is not modified; phosphorylation was ruled 
out [36]. So we suggest hat the post-translational modi- 
fication of the 210FGF-2 is located in the N-terminal 
domain. The only post-translational modification as yet 
identified in the N-terminal part of the high molecular 
weight FGF-2 is the dimethylation of arginines which 
takes place in glycine-arginine blocks [24]. The addi- 
tional mass brought by the dimethylation of arginines 
(11 putative sites) cannot totally explain the 1 kDa differ- 
ence between 2 1 OFGF-2 and r2 l OFGF-2. Conformation 
induced by methylation could explain the observed ab- 
normal electrophoretic migration. However additional 
uncharacterized modifications cannot be excluded. 
3.6. Biological assay 
S-Zephyr purified r210FGF-2 was tested for its mito- 
genie activity on ABAE cells and compared with the 
r146FGF-2 (Fig. 6). All proteins presented the same abil- 
ity to support growth and were comparable to the 146 
amino acid FGF-2 form isolated from tissue [37]. 
4. Conclusion 
This paper reports the production and purification to 
homogeneity of biologically active r210FGF-2. The pro- 
tein is synthetized in the native form from a T7 RNA 
polymerase expression vector. Structural characteriza- 
tion by mass spectrometric analysis reveals a correct 
molecular mass with regard to the primary sequence. 
The high molecular weight molecule of FGF-2 is how- 
ever susceptible to maturation into a 148 amino acid 
form. The complexicity of FGF-2 with four proteins 
encoded by a single mRNA is poorly understood and our 
system provides an abundant source of new recombinant 
FGF-2 to analyse structure/function or to test particular 
biological activities of the 210 amino acid FGF-2 form. 
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